期刊文献+

微小RNA在卵巢癌中的作用 被引量:2

Function of microRNAs in ovarian cancer
原文传递
导出
摘要 微小RNA(miRNA)在卵巢癌中表达明显改变。基于微阵列芯片检测的卵巢癌相关miRNA表达谱和后续的对个别miRNA的深入研究,发现其与卵巢癌的发生、发展、复发、耐药等密切相关,有望用于卵巢癌早期诊断、复发检测、预后判定及治疗。 The expression of microRNAs (miRNAs) alters obviously in ovarian cancer. Through miRNA profile based on a microarray platform and further research on individual one, they are found to be closely related to pathogenesis, progression, recurrence, and drug resistance of ovarian cancer and have a good prospect in applying it in the early diagnosis, detection recurrence, prognosis and therapy of ovarian cancer.
出处 《国际肿瘤学杂志》 CAS 2011年第10期790-793,共4页 Journal of International Oncology
关键词 微RNAS 卵巢肿瘤 诊断 治疗 MicroRNAs Ovarian neoplasms Diagnosis Therapy
  • 相关文献

参考文献19

  • 1Resnick KE, Aider H, Hagan JP, et al. The detection of differen tially expressed mieroRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 2009, 112 (1) : 55-59.
  • 2Pearman JW, Bailey M, Riley LP. Bladder installations of trisdine compared with catheter introducer for reduction of bacteria during intermittent catheterization of patients with acute spinal cord trauma[J]. Br J Urol, 1991, 67(?): 483-490.
  • 3Nam E J, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 2008, 14 ( 9 ) : 2690- 2695.
  • 4Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci[J]. Clin Microbiol Rev, 1994, 7(1): 117-140.
  • 5Sorrentino A, Liu CG, Addario A, et al. Role of mieroRNAs in drug- resistant ovarian cancer cells. Gynecol Oncol, 2008, 111 (3) : 478- 486.
  • 6Li J, Liang S, Yu H, et al. An inhibitory effect of miR-22 on cell migration and invasion in ovarian eancer. Gynecol Oncol, 2010, 119 ( 3 ) : 543-548.
  • 7Comey DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res, 2010, 16 (4) : 1119-1128..
  • 8Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Bial Ther, 2008, 7(2) : 255-264.
  • 9Guan Y, Yao H, Zheng Z, et al. MiR-125b targets BCL3 and sup- presses ovarian cancer proliferation. Int J Cancer, 2010, 128 ( 10 ) : 2274-2283.
  • 10Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-21g induces cell survival and cisplatinresistance by targeting PTEN. Cancer Res, 2008, 68 (2) : 425-433.

共引文献1

同被引文献31

  • 1徐卫,李建勇,陆凤翔.微小RNA及其在恶性淋巴增殖性疾病中作用的研究进展[J].中国实验血液学杂志,2006,14(4):840-844. 被引量:4
  • 2Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer [J]. BMC Cancer, 2013, 13:72.
  • 3Suryawanshi S, Vlad AM, Lin HM, et al. Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associatcd Ovarian Cancer [J]. Clin Cancer Res, 2013, 19(5): 1213-1224.
  • 4Kau CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer [J]. BMC Cancer, 2012, 12: 627.
  • 5Li Y,VandenBoom TG 2nd,Kong D. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelialmesenchymal transition in gemcitabine resistant pancreatic cancer cells[J].Cancer Research,2009,(16):6704-6712.
  • 6Gregory PA,Bracken CP,Smith E. An autocrine TGF-β/ZEB/ miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition[J].Molecular Biology of the Cell,2011.1686-1698.
  • 7Schliekelman MJ,Gibbons DL,Faca VM. Target of the Tumor Suppressor miR200 in Regulation of the Epithelial-Mesenchmal Transition in Cancer[J].Cancer Research,2011,(24):7670-7682.
  • 8Marchini S,Cavalieri D,Fruscio R. Association between miR-200c and the survival of patients with stage Ⅰ epithelial ovarian cancer:a retrospective study of two independent tumour tissue collections[J].The Lancet Oncology,2011,(03):273-285.
  • 9Cochrane DR,Spoelstra NS,Howe EN. MicroRNA-200c mitigates invasiveness and restores agents sensitivity to microtubule-targeting chemotherapeutic agents[J].Molecular Cancer Therapeutics,2009,(05):1055-1066.
  • 10陈金虹,Karen KL CHAN,Kar Fai TAM,Hextan YS NGAN.未行淋巴清扫的早期卵巢癌81例生存率的回顾性分析[J].肿瘤,2008,28(12):1059-1063. 被引量:3

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部